Metaflammation, an atypical, metabolically induced, chronic lowgrade inflammation, plays an important role in the development of obesity, diabetes and atherosclerosis. An important primer for metaflammation is the persistent metabolic overloading of the endoplasmic reticulum (ER), leading to its functional impairment. Activation of the unfolded protein response (UPR), a homeostatic regulatory network that responds to ER stress, is a hallmark of all stages of atherosclerotic plaque formation. The most conserved ER-resident UPR regulator, the kinase/endoribonuclease IRE1, is activated in lipid-laden macrophages that infiltrate the atherosclerotic lesions. Using RNA sequencing in macrophages, we discovered that IRE1 regulates the expression of many proatherogenic genes, including several important cytokines and chemokines. We show that IRE1 inhibitors uncouple lipid-induced ER stress from inflammasome activation in both mouse and human macrophages. In vivo, these IRE1 inhibitors led to a significant decrease in hyperlipidemia-induced IL-1b and IL-18 production, lowered T helper type-1 immune responses and reduced atherosclerotic plaque size without altering the plasma lipid profiles in apolipoprotein E-deficient mice. These results demonstrate that pharmacologic modulation of IRE1 counteracts metaflammation and alleviates atherosclerosis.
INTRODUCTION
Complex molecular interactions between environment, diet and genetics that take place at the metabolic and immune interface provoke a low-grade, chronic inflammatory response -metaflammationthat engages cells of the immune system (macrophages, neutrophils, and lymphocytes) and metabolic tissues (adipocytes, hepatocytes and pancreatic cells) (1). An important primer for metaflammation is chronic metabolic overloading of organelles, such as the endoplasmic reticulum (ER) and mitochondria, which results in impairment of their functions (2) .
The ER serves essential cellular functions that include the synthesis and folding of secreted and transmembrane proteins, calcium storage, and lipid synthesis for membrane biogenesis or energy storage. Disruption of any of these functions leads to ER stress, and the subsequent activation of an elaborate network of adaptive responses, collectively known as the unfolded protein response (UPR) (3) . The UPR re-establishes homeostasis through both transcriptional and translational layers of control. The UPR signals through three mechanistically distinct branches that are initiated by the ER-resident protein folding sensors IRE1 (inositol-requiring enzyme 1), PERK (protein kinase RNA-like ER kinase), and ATF6 (activating transcription factor 6) (3).
IRE1 controls the phylogenetically most conserved branch of the UPR, found from fungi to metazoans. It has an ER-lumenal sensor domain that recognizes unfolded pep-tides, and cytosolic kinase and endoribonuclease (RNase) domains that relay the information to downstream effectors (3) . Upon sensing unfolded proteins, IRE1 oligomerizes and transautophosphorylates, thereby activating its RNase function. Metazoan IRE1 possesses two functional outputs dependent on its RNase activity: i) it initiates a non-conventional splicing reaction that processes the mRNA encoding XBP1 (X-box binding protein-1) to allow the translation of its active form, XBP1s, a potent transcription factor that, together with ATF6, drives expression of numerous genes, including those encoding ERresident chaperones and ER-associated protein degradation machinery (3) . ii) IRE1 selectively degrades ER-bound mRNAs in a process known as regulated IRE1-dependent decay (RIDD) to alleviate ER load (4) . By these mechanisms, UPR activation reinstates homeostasis.
Increased ER stress and activation of the UPR are well documented in atherosclerosis (5) . Many metabolic cardiovascular risk factors observed in obesity, including hyperglycemia, hypercholesterolemia, and elevated saturated fats, can induce ER stress in all stages of atherogenesis, the process leading to the development of atherosclerotic plaques. During atherogenesis, a maladaptive inflammatory response is initiated by the deposition of cholesterol-rich lipoproteins in the sub-endothelial layer of arterial walls (6) . Signs of ER stress are most prominent in the atherosclerosis-prone regions of vascular lesions, such as the branching points of arteries, and are typically observed in macrophages -among other immune cells-infiltrating these regions (7, 8) . Chronic, irremediable ER stress triggers apoptosis in macrophages, contributing to the growth of the necrotic core that is observed in atherosclerotic plaques, which leads to a subsequent reduction in plaque stability, promoting their rupture (5) .
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Work over the last decade has pinpointed ER stress as a driving force for atherosclerosis progression (5, (7) (8) (9) (10) . For example, inhibiting the apoptotic signaling downstream of ER stress through genetic deletion of the pro-apoptotic transcription factor CHOP (CCAAT box-binding enhancer homologous protein) or the signal transducer JNK (c-Jun N-terminal kinase) blocks atherosclerosis progression (5, (11) (12) (13) . Moreover, modulation of ER stress by using chemical chaperones alleviates atherosclerosis; further supporting the idea that therapeutic modulation of ER function is a promising avenue to combat atherosclerosis (14) (15) (16) . Precedence for this notion is provided by pharmacological approaches to improve ER functionand thereby limit ER stressthat include autophagy inducers, antioxidants, regulators of ER calcium homeostasis (17) (18) (19) .
Recent drug discovery efforts have opened the door to approaches that entail selective modulation of UPR signaling. This quest has led to the identification of several new small molecules that target the enzymatic activities of specific UPR regulators (19) (20) (21) (22) (23) . Specifically, blocking IRE1 or XBP1s function has been shown to be beneficial for restraining tumor progression in mouse models (21, 24) , highlighting that the specific targeting of the UPR can have beneficial impact in disease.
Several lines of evidence support the notion that selective pharmacological targeting of IRE1 is a desirable therapeutic approach for treatment of atherosclerosis. First, a profound increase in IRE1 phosphorylation and XBP1s expression is observed in atherosclerotic plaques of mice and humans (8, 10) . Second, mechanical sheer stresses activate IRE1, while cardiovascular disease risk factors, such as oxidized phospholipids and homocysteine, induce both IRE1 and PERK (5, (25) (26) (27) (28) (29) . Third, experimentally sustained XBP1 mRNA splicing in the vessel wall promotes atherosclerosis, whereas its ablation ameliorates hypercholesterolemia in obese or Apolipoprotein E-deficient (ApoE -/-) mice (10, 30) . Two small molecules, STF-083010 and 4µ8C, which selectively inhibit IRE1's RNase function, have been used in 137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156 Submission PDF cells and animals to produce favorable therapeutic outcomes in other disease settings: STF-083010 reduced growth of multiple myeloma (21, 24, 31, 32) , and 4µ8c suppressed inflammation in a murine arthritis model (33) . The action of both compounds is well understood mechanistically. Both form a Schiff base with a specific lysine positioned in the active site of the IRE1 RNase domain, blocking its function, and both show no overt toxicity when administered systemically (21, 32, 33) . Thus, we reasoned that these drugs might have therapeutic applicability in atherosclerosis.
Here we investigated the direct contribution of IRE1 to lipidinduced inflammation and to atherosclerotic disease progression by administering these two IRE1 inhibitors to macrophages and to ApoE -/mice on a Western-type (high fat) diet. Our results substantiate the concept that specific pharmacological modulation of IRE1 counteracts metaflammation and yields therapeutic gains in atherosclerotic disease, warranting further validation in human disease.
RESULTS

Pro-atherogenic genes are regulated by IRE1
To understand the contributions of IRE1 in atherogenesis, we first analyzed the impact of its inhibition on the transcriptome of macrophages using RNA-seq. ER poisons, such as tunicamycin, which inhibits protein N-linked glycosylation in the ER lumen, or thapsigargin, which disrupts ER calcium reuptake, activate all UPR branches simultaneously, impeding the dissection of the signaling contributions of individual UPR branches. By refraining from using these pleiotropic drugs, we aimed to identify the specific IRE1-regulated gene expression changes. To this end, we probed the transcriptional response to acute inhibition of IRE1 using STF-083010 in primary mouse bone marrow-derived macrophages (BMDMs) (34, 35) . We analyzed differentially regulated mRNAs at early time points (6 hours) after IRE1 inhibition to distinguish immediate-responsive genes from those whose expression may be altered as part of an adaptive response to chronic inhibition. Using an arbitrary cut-off of 1.5-fold, we observed increased expression of 169 genes and decreased expression of 135 genes upon IRE1 inhibition ( Fig. 1A , S. Table 1 and S.Table 2 ; p<0.05). To categorize the affected genes functionally according to their association with disease processes, we employed the Ingenuity Pathway Analysis (IPA) tool (36) . IPA identified the downregulation of many important pro-atherogenic genes, including cytokines, chemokines, and chemokine receptors upon inhibition of the steady-state IRE1 activity ( Fig. 1B) .
We next validated our findings using quantitative reverse transcription polymerase chain reaction (qRT-PCR). In these experiments, we observed a significant reduction in the mRNA levels of IL-1β (interleukin-1β), CCL2 (C-C Motif Chemokine Ligand 2), S100A8 (calgranulin A) and MMP9 (ma-409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476   4 www.pnas.org ------Footline Author   477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544 Submission PDF trix metalloprotease-9) (p<0.05, p<0.001, p<0.01, p<0.01, respectively), following IRE1 inhibition either with STF-083010 or 4µ8c ( Fig. 1C -E, S. Fig. 1A -E). Both of these drugs were used at concentrations that do not compromise cell viability or induce any other toxicity (21, 34, 35, (37) (38) (39) (40) . Consistent with earlier reports, these IRE1 inhibitors had no effect on the kinase function of IRE1 (S. Fig.1F-1H ), confirming that the identified pro-atherogetic genes are regulated by IRE1's RNase activity.
Since IRE1 is rate-limiting for the production of XBP1s, we next assessed if XBP1s regulates the expression of these proatherogenic genes. To this end, we forced expressed XBP1s or restored IRE1 function in IRE1-deficient (IRE1 -/-) mouse embryonic fibroblasts (MEF) (S. Fig.1I ). Both experiments showed a marked induction of IL-1β, CCL2, and S100A8 mRNA levels ( Fig. 1F-H ). Together, our findings confirm that the IRE1-XBP1 signaling branch of the UPR maintains the expression of key proatherogenic cytokines and chemokines in macrophages.
Induction of IL-1β and CCL2 depends on IRE1 during lipotoxicity
Our finding that IRE1 maintains the expression of several important, pro-atherogenic genes in macrophages suggests that, when induced by metabolic stress, heightened IRE1 activity could drive the atherosclerotic process. One important activating signal for the UPR in macrophages is exposure to excessive amounts of lipids, which elicits toxicity (14, 28, 41) . This lipotoxicity results in increased production of reactive oxygen species (ROS), ER stress, and inflammation, and can result in apoptosis (41) .
Based on these observations, we next investigated if lipidinduced IRE1 activation plays a role in IL-1β induction. Inhibition of IRE1 with STF-083010 led to a significant block in lipidinduced IL-1β mRNA production and secretion from BMDMs ( Fig. 2A-B , S. Fig.2A-B ). As expected, inhibition of IRE1 activity with 4µ8c showed the same effects (S. Fig. 2C -F). To further delineate the role of IRE1 and XBP1s in the regulation of IL-1β, we transfected BMDMs with a specific small interfering RNAs (siRNAs). We found that expression of siRNAs against IRE1α □(the ubiquitously expressed IRE1 homolog) or against XBP1 resulted in a significant reduction in lipid-induced IL-1β mRNA production and IL-1β secretion in BMDMs ( 545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612 Footline Author PNAS Issue Date Volume Issue Number  5   613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638  639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680 Submission PDF by pre-incubation with 4µ8c ( Fig. 2E -F, S. Fig. 2I ). These findings show that IRE1-XBP1 signaling plays an important role in IL-1β mRNA up-regulation and secretion from both mouse and human macrophages.
We also investigated if the pro-atherogenic chemokine CCL2 is regulated by IRE1 under lipotoxic ER stress conditions. Both STF-083010 and 4µ8c treatment of BMDMs resulted in complete inhibition of lipid-induced CCL2 mRNA production and protein secretion (S. Fig. 3A-C) . Consistent with this observation, siRNAs against IRE1α or XBP1 also suppressed lipid-induced CCL2 production and secretion in BMDMs (S. Fig. 3D-E) . Moreover, 4μ8c blocked lipid-induced CCL2 production in human PBMCs (S. Fig.  3F ). Collectively, these data show that IRE1 is important for the inflammatory response to lipids and for the production of proatherogenic cytokines in both mouse and human macrophages.
Inflammasome activation depends on IRE1 during lipotoxicity
Because IRE1 inhibition leads to a strong suppression of IL-1 β secretion, we reasoned that IRE1 may contribute to the lipid-induced activation of the NLRP3 (Nod-like receptor family, pyrin domain containing protein-3) inflammasome, a multicomponent platform that contains caspase-1 and induces the caspase-1-dependent secretion of the pro-inflammatory cytokines IL-1β and IL-18 (42, 43) . Previous studies showed that ER stress induces inflammasome activation through several mechanisms including calcium mobilization and the release of reactive oxygen species (mtROS) from damaged mitochondria (44) . Because earlier studies from our and other laboratories showed that treatment of macrophages with saturated fatty acids activate IRE1, and because these lipids specifically activated the NLRP3 inflammasome through inducing mtROS production, we sought to investigate this connection further (42, 43, 45) . To this end, we first measured mtROS production in cells exposed to lipotoxic stress in the presence of IRE1 inhibitors. We observed that lipidinduced ER stress in BMDMs resulted in a dramatic elevation of mtROS, which was completely blocked by 4μ8c treatment as well as by XBP1 knock down (Fig. 3A-3B and S.Fig. 4A ).
The impact of IRE1 signaling on inflammasome activation has been postulated to be mediated by the IRE1-dependent accumulation of the thioredoxin-interacting protein (TXNIP), a thioredoxin inhibitor whose increased levels promote activation of the NLRP3 inflammasome (35) . In stark contrast to these earlier findings, which used cells treated with canonical ER poisons, lipid-induced ER stress led to a profound suppression of TXNIP in macrophages which was partially blocked by inhibiting IRE1 (S. Fig. 4B ). Another mechanism by which ER stress can induce mitochondrial oxidative stress and activation of the NLRP3 inflammasome complex is through calcium mobilization (46) . Indeed, we observed PA leads to a significant increase (3 fold) of calcium levels in the mitochondria, but this could not be prevented by IRE1 inhibition (S. Fig. 4C ). Moreover, lipid-induced ER stress also induced pro-caspase-1 maturation (indicated by the appearance of the p10 fragment), an effect that was reduced by treatment with IRE1 inhibitors or siRNA-mediated silencing of IRE1α and XBP1 (Fig. 3C, S.Fig.4D-E) . Taken together these results indicate that IRE1 plays a crucial role in perpetuating mtROS production and NLRP3 inflammasome activation in cells experiencing lipotoxic ER stress, but that this effect is independent of TXNIP induction and calcium mobilization.
We further investigated if IRE1 affects the activation of the NLRP3 inflammasome by other stimuli or the activation of different inflammasome complexes by specific inducers. While IRE1 inhibition blocked NLRP3 inflammasome activation, cleavage of caspase-1 and secretion of IL-1β by various different NLRP3 inflammasome inducers (including ATP, Alum and cholesterol crystals) ( Fig. 3D) , it did not alter the activation of other inflammasome complexes such as NLRC4 (NLR family CARD domain containing protein 4) by flagellin or AIM2 (absent in melanoma 2) by poly (deoxyadenylic-deoxythymidylic acid) (poly (dA:dT)) as evident by no changes in caspase-1 cleavage (Fig.3E ). Since IRE1-XBP1 controls IL-1β mRNA production, we observed reduction in secreted IL-1β protein levels in all of the treatments (Fig. 3D-3E ). Finally, together with our results showing IRE1 induces IL-1β,our data demonstrate that IRE1 plays a major role in controlling IL-1β signaling, both transcriptionally and by promotion of its maturation via the activation of the NLRP3 inflammasome.
Pharmacological inhibition of IRE1 combats atherosclerosis
The evidence presented above, in conjunction with previous results showing that restoring or improving ER function alleviates atherosclerosis (14, 17, 47) , suggests that inhibiting IRE1 may impair atherosclerosis progression. Therefore, we postulated that administration of IRE1 modulators might have beneficial effects by limiting the inflammatory signaling associated with elevated ER stress in a mouse model of atherosclerosis. To test this notion, we challenged ApoE -/mice with a Western diet (12 weeks) and then treated them daily with STF-083010 by intraperitoneal injection (6 weeks) (Fig. 4A ). Even though limited pharmacodynamic data is available for the IRE1 inhibitors we employed, target engagement has been shown in cells and tissues (21, 39) . We based our in vivo drug dosage and delivery on earlier in vivo studies that Submission PDF successfully administered the IRE1 modulators without toxicity (21, 24, 31) . Furthermore, we confirmed target engagement in tissues by assessing drug-induced suppression of XBP1 mRNA splicing and RIDD activities by observing a significant reduction in XBP1s mRNA (p<0.05) and a modest increase in canonical RIDD target mRNAs (p<0.05), respectively (S. Fig.5 A-C) . Importantly, the IRE inhibitor we employed did not alter IRE1 phosphorylation in vivo (S. Fig.5D ). Furthermore, we detected no differences in body weights, blood glucose levels, liver morphology, plasma alanine amino transferase (ALT) activity and cholesterol profiles between the STF-083010-treated and control groups (S. Table 3 ; S. Fig. 5E-F and 6) . However, the analysis of en face aorta preparations showed that chronic administration of STF-083010 led to a significant decrease (35.8%; p<0.001) in atherosclerotic lesions when compared to the control group (Fig. 4B) . Furthermore, when we evaluated the impact of STF-0803010 on plaque development in the aortic root, we observed a significant reduction (21.4%, p<0.001) in the foam cell area (visualized by Oil Red O staining) in the inhibitor-treated group when compared to control mice (Fig. 4C) .
Analogous experiments using 4μ8c in the same animal model (using previously published doses that showed no toxicity; (33, 37, 40, 48) ) produced similar results (Figs. 4D-F): 4μ8c treatment led to a significant reduction (45.2%; p<0.001) in atherosclerotic lesion area in en face aorta preparations (Fig.4E ), a significant reduction in XBP1s mRNA (S. Fig. 7A ; p<0.05), but no change in IRE1 phosphorylation in the spleens (S. Fig.7B ). Furthermore, 4μ8c treatment led to a reduced foam cell area (Fig. 4F ), without overt differences in body weight, blood glucose levels (S. Table 4 ), liver morphology and plasma ALT activity between the inhibitor treated and control mice (S. Fig.7C-D) . These in vivo findings demonstrate that pharmacological inhibition of IRE1 can effectively mitigate plaque development in mice.
Pharmacological inhibition of IRE1 alters plaque composition
Endothelial cells (ECs), vascular smooth muscle cells (VSMCs), and immune cells such as lymphocytes, dendritic cells, neutrophils and macrophages play important roles in the development of atherosclerotic plaques in the arterial wall. The UPR is activated in many of these cell types and at all stages of atherosclerotic plaque development. This increase in ER stress is also associated with plaque progression, vulnerability to rupture, and acute coronary syndrome in humans (7) . Given that IRE1 inhibitors alleviated atherosclerosis in ApoE -/mice, we next analyzed the impact of these inhibitors on the cellular composition of the lesions. STF-083010 treatment led to a significant reduction (35%; p<0.01) in macrophages (as visualized by MOMA-2 staining) infiltrating the aortic root plaques (Fig. 5A ). This reduction in macrophage numbers was not the product of increased apoptosis as determined by TUNEL assays in macrophage-enriched areas of the plaques (Fig. 5B ). Furthermore, there were no differences in the necrotic core area between the treatment and control groups (S. Fig. 8A ). During plaque formation, VSMCs migrate from adventitia to intima, secreting collagen and sealing the fibrous cap of the plaque. The analysis of the lesions in STF-083010-treated mice (with Mason's Trichrome staining) showed there is a significant increase in collagen content that is responsible for tensile strength and elasticity of the plaques (22%; p<0.05) without changes in the numbers of the VSMCs infiltrating the lesions (S. Fig. 8B-8D ). However, we did not observe significant differences in the fibrous cap thickness between the treatment and control groups (S. Fig.8C ) Finally, STF-083010 treatment did not alter CD3+ T cell numbers in the adventia/lesions (S. Fig. 8E ). Taken together, these results indicate that the major consequences of IRE1 inhibition include a reduction in macrophages in and an increase in collagen deposition in atherosclerotic plaques.
Last, we sought in vivo evidence for the observed inhibition of IL-1β by IRE1 inhibition in macrophages ( Figs. 1 and 2) . We observed that STF-083010 treatment reduced the expression of IL-1β in the aortic root lesions stained with a specific antibody against IL-1β ( Fig. 5C ). Together, these results validate our earlier in vitro findings and demonstrate the anti-atherogenic effect of IRE1 inhibitors involves a blockage of inflammation in the lesions.
IRE1 inhibitors suppress hyperlipidemia-induced Th-1 immune responses
Atherosclerosis initiation and progression depend on both innate and adaptive immunity pathways. T cells orchestrate adaptive immunity while macrophages bridge innate and adaptive immune processes that contribute to lesion development. T-helper (Th) cells form the majority of lymphocytes in the atherosclerotic plaques. Th-1 cells are pro-inflammatory, produce high amounts of IFN-γ, and contribute to the progression of atherosclerosis. Two other types of lymphocytes implicated in atherosclerosis progression include Th-2 cells, which produce IL-4, and Th-17 cells, which produce IL-17 (49) (50) (51) . The inflammasome-induced cytokines IL-18 and IL-1β, play an important role in the polarization of Th-1 and Th-17 responses (52) . Since inhibition of IRE1 suppressed inflammasome activation ( Fig.3C and S.Fig. 4D -E) and IL-1β production in lipid-challenged macrophages (Fig.2) , as well as in lesions and tissues (Fig. 5C, S.Fig. 9A-B) , we next assessed the impact of IRE1 inhibition on systemic IL-18 levels and Th cell differentiation in hyperlipidemic mice. ApoE -/mice (on Western diet) that were treated with STF-083010 displayed a significant decrease in plasma IL-18 levels (Fig.6A; p<0 .05) and a marked reduction in the secretion of IFN-γ -but not of IL-4 or IL-17-from splenocytes (Fig. 6B; p<0 .001; Fig. 6C -D, S. Fig. 9C-E) . We did not observe changes in the overall T cell counts in atherosclerotic lesions after STF-083010 treatment (S. Fig. 8E ), indicating that decreased lymphokine production is intrinsic to intracellular signaling and does not result from a decline in the infiltrating immune cells that produce them. In conclusion, the reduced inflammasome activity in these mice (as measured by IL-1β and IL-18 levels in Fig.5C and 6A ) after STF-083010 treatment correlates with the suppression of the Th-1 inflammatory response that is known to promote atherosclerosis development.
DISCUSSION
Studies in mice and humans suggest that chronic ER stress plays an important role in atherosclerosis progression. Therefore, pharmacological manipulation of the UPR -the network of signaling pathways that respond to ER stress-represents a promising therapeutic approach to manage atherosclerosis (7, 14, 53) . The recent discovery of highly selective UPR modulators provides unique opportunities to investigate the contribution of individual UPR branches to the pathogenesis of this disease. Using small molecules that target IRE1, we showed that modulating IRE1 signaling counteracts atherosclerotic plaque formation in mouse models.
First, IRE1 inhibition altered plaque cellular composition mainly by reducing the numbers of macrophages in the atherosclerotic lesions without altering apoptosis. We infer that this effect is likely to stem from reduction in CCL2, a strong macrophage chemo-attractant, consistent with our observations in macrophages treated with IRE1 inhibitors. Alternatively, IRE1 modulators could impact macrophage clearance from lesions by phagocytosis of dying cells. We observed no change in the apoptotic cell counts in lesions, arguing against this possibility. Nevertheless, more detailed future studies are required to discriminate between these two possibilities.
Second, IRE1 inhibitor-treated mice displayed an increased collagen content in atherosclerotic lesions, which imparts tensile Submission PDF strength and elasticity to the plaques (54) . However, we did not observe an increase in fibrous cap thickness upon IRE1 inhibitor treatment. Because we observed no differences in the number of VSMCs in the lesions, the increased collagen deposition may be related to increased collagen folding and secretion, which is consequential to enhanced ER function coupled to reduced cleavage by matrix metalloproteases (MMPs). In fact, early in our study we observed that MMP9 is regulated by IRE1, while another study reported RIDD-dependent collagen degradation during ER stress (55) . Both observations lend support to our findings and substantiate our hypotheses.
Third, the results from our RNA-seq analyses in macrophages that were treated with IRE1 inhibitors strongly hinted at IRE1's involvement in the production of several pro-atherogenic cytokines, chemokines, and their receptors including IL-1β, CCL2 and chemokine receptor 2 (CCR2). Indeed, IRE1, through XBP1s, regulates IL-1β and CCL2 mRNA induction in lipid stressed macrophages. Moreover, oxidative stress can activate NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) and production of CCL2, resulting in the recruitment of monocytes to a growing plaque (7) .
Fourth, cholesterol crystals, saturated fatty acids, and ROS accumulate in plaque areas and provide activation signals for activation the NLRP3 inflammasome and subsequent secretion of IL-1β and IL-18 (44) . These cytokines generate Th-1-type immune responses that promote plaque progression and unstable lesions (52) . Treatment of macrophages with the IRE1 inhibitors suppressed lipid-induced mtROS production and activation of the NLRP3 inflammasome, and subsequent IL-1β secretion. Our results therefore implicate IRE1 activation in the perpetuation of lipid-induced mitochondrial oxidative stress upstream of NLRP3 inflammasome activation, but our data show that this effect is independent of TXNIP induction or calcium mobilization (35, 44) . Macrophage mitochondrial oxidative stress plays an important role in atherogenesis by amplifying inflammation (56) . Our results reveal IRE1 is crucial for the regulation of mtROS generation during lipid-induced ER stress; however, future detailed studies will be needed to uncover how this is achieved by IRE1. In addition to our findings in cells, we confirmed the inhibitory effect of IRE1 inhibitors on hypercholesterolemia-induced IL-1β and IL-18 production in vivo, in plaques and in plasma, respectively. Consistent with these observations, treatment with IRE1 inhibitors led to a marked suppression of hyperlipidemiainduced Th-1 immune responses in these mice. We observed no differences in T cell numbers in adventia/lesions between the IRE1 inhibitor treatment and control groups, and previous studies have shown the IRE1 inhibitor used in this study does not affect T regulatory cells (33, 37) Collectively, these findings show that prevention of inflammasome-associated cytokine production by IRE1 inhibitors in vivo has dramatic effects on counteracting atherosclerotic disease progression. Our findings correlating suppression IL-1β with atheroprotection are timely in view of a major ongoing clinical trial on the effect of an anti-IL1β trial in coronary artery disease (by Cantos). While our data show a clear impact of IRE1 inhibition on macrophage inflammatory functions, activation of the UPR also occurs in many other lesion-resident cell types. Thus, our results do not exclude the possibility that the antiatherogenic effects of IRE1 inhibition could also involve other lesion-resident cell types that contribute to atherogenesis.
Fifth, the reduction in plaque inflammation and size occurred independent of a correction of elevated plasma lipid levels of IRE1 inhibitor-treated ApoE -/mice. This notion contrasts with results of a previous study, in which mice bearing a liver-specific deletion of XBP1 displayed a profound reduction in plasma cholesterol and triglyceride levels (57) . However, it is important to note that this apparent disparity may exclusively result from feedback activation of IRE1 upon genetic loss of XBP1 (57) .
Notably, additional siRNA-mediated IRE1 depletion partially reverted the hypolipidemic phenotype in vivo, hinting at a RIDDdependent function that controls lipid metabolism (30) . Furthermore, we did not observe feedback activation of IRE1 or any signs of liver toxicity with the IRE1 modulators. Since XBP1s promotes the transcriptional upregulation of a lipogenic gene program, these findings could be interpreted to mean that the splicing and RIDD outputs of IRE1 have opposing effects on lipid metabolism (30) . While most of the direct targets of XBP1 participating in triglyceride and sterol lipogenic programs were also identified as RIDD substrates in this study (Ref 30, Fig. 3 ), IRE1 (through its RIDD modality) seems to be able to reduce the steady-state expression of a larger number of lipogenic genes independent of XBP1, hinting at a complex lipogenic regulatory program that depends on the interplay between XBP1 and IRE1 signaling (30, 57) . Thus, the reduction in plaque size we observed in our study is likely to result from IRE1 inhibitor-mediated anti-inflammatory changes and not the product of changes in lipid metabolism.
While we have seen important gains in mitigating atherosclerosis by pharmacologically targeting IRE1 in our experimental models, it is important to note that the other UPR branches, particularly the PERK-CHOP branch, are also induced as atherosclerosis progresses and appear to be instrumental for macrophage apoptosis (5, 11) . Previous studies focusing on the engagement of apoptotic pathways initiated by the UPR (such as those mediated by CHOP and JNK) showed that mice deficient for these apoptotic effectors are protected from atherosclerosis (5, (11) (12) (13) . Independent of CHOP or JNK engagement, here we found that modulating IRE1 signaling in vivo with small molecule IRE1 inhibitors modifies a different branch of UPR signaling that impinges on metaflammation and alters the course of atherosclerosis. These results support the notion that it may be possible to uncouple metabolically induced ER stress from inflammation by calibrating UPR signaling, thereby improving the clinical outcome of atherosclerosis. With the advent of specific inhibitors that can target different UPR branches, exploring the efficacy of combinatorial UPR calibration in this chronic disease setting becomes a promising endeavor.
EXPERIMENTAL PROCEDURES
A list of primers used in the study can be found in the supplemental materials.
Reagents and Plasmids IRE1 -/-MEFs were provided by Gokhan Hotamişligil (Harvard School of Public Health). BMDMs were isolated from of C57BL/6 mice. Plasmids encoding XBP1s (21833), wt IRE1α (13009) were purchased from Addgene. L-Glutamine, Dulbecco's modified Eagle's medium (DMEM), phosphate buffered saline (PBS), Hank's balanced salt solution (HBSS), penicillin/streptomycin (P/S), fetal bovine serum (FBS), and RPMI-1640 medium were obtained from Thermo Scientific or HyClone (GE Healthcare Life Sciences). Trypsin, ampicillin, kanamycin, Bradford assay reagents, ultrapure lipopolysaccharides (LPS), palmitic acid (PA), phosphatase inhibitor cocktail, and STF-083010 were purchased from Sigma. 4μ8c was purchased from Calbiochem. Primary antibodies used for immunoblotting were purchased from the following suppliers: Anti-IRE1 phospho S724 antibody (Abcam ab48187), IL-1β (Abcam ab9722), IRE1α Rabbit mAb (3294, Cell Signaling), β-Actin (sc-47778, Santa Cruz Biotechnology), β-actin (sc-9104, Santa Cruz Biotechnology), Caspase-1 (M20) (sc-514, Santa Cruz Biotechnology) and IL-1β (R&D Systems AF-401-NA). Enhanced chemiluminescence Prime Western Blot Detection Kit was purchased from Amersham Pharmacia. ALT assay (Sigma MAK052).
Preparation of PA-bovine serum albumin complex PA was dissolved in absolute ethanol to yield a stock concentration of 500 mM and stored at −80°C. Stock PA was diluted to the working concentration and suspended with 1% fatty acid free BSA in RPMI-1640 medium (without serum) by mixing at 50°C for 30 minutes.
Preparation of Cholesterol Crystal 10 mg/mL cholesterol solution was prepared in ethanol and was heated to 60 0 C and brought to room temperature to allow for crystallization, washed with PBS, and resuspended in RPMI-1640 medium at 5 mg/mL. 400μg/ml cholesterol crystals were used for treating the cells (for 20 hours) as described (58) .
Cell Culture and Treatments Isolation of BMDMs: Bone marrows were collected from the tibia and femurs of mice into RPMI-1640 medium containing 1% penicillin/streptomycin
